Literature DB >> 28474166

Undisturbed local bone formation capacity in patients with atypical femoral fractures: a case series.

H P Bögl1, P Aspenberg1, J Schilcher2.   

Abstract

We excised the fracture site in 8 patients with incomplete atypical femoral fractures by drilling an 11-mm-diameter hole. New bone formation could be seen in the hole within a normal time frame. Delayed healing of these fractures might be unrelated to an impaired capacity to form bone.
INTRODUCTION: Incomplete atypical femoral fractures (undisplaced cracks) heal slowly or not at all, and often progress to a complete fracture with minimal trauma. The impaired healing has been attributed to an impaired biologic healing capacity related to bisphosphonate use, or, alternatively, to the mechanical environment within the fracture crack. This study aimed to investigate the capacity for bone formation after resection of the fracture site.
METHODS: Between 2008 and 2014, we recruited eight patients with incomplete atypical femoral fractures. All used oral bisphosphonates before the fracture for on average 8 years (range 4 to 15) and complained of thigh pain. The fractures were stabilized with reamed cephalomedullary nails. During surgery, the fracture site in the lateral cortex was resected with a cylindrical drill (diameter 11.5 mm). The cylindrical cortical defect allowed radiographic evaluation of new bone formation, and the patients were followed clinically and radiologically for 24 months (range 15 to 92).
RESULTS: After 3 months, newly formed bone could be seen in the cortical defects in all patients. After 13-26 months, the previous defects showed continuous cortical bone. At final follow-up, all patients reported full recovery of pre-surgical complaints. No complications occurred and no reoperations were performed.
CONCLUSIONS: New bone formation occurred within a time frame that appears normal for healing of cortical bone defects. This suggests that the capacity to form new bone is intact.

Entities:  

Keywords:  Atypical femoral fracture; Bisphosphonates; Fracture healing; Osteoporosis

Mesh:

Substances:

Year:  2017        PMID: 28474166     DOI: 10.1007/s00198-017-4058-4

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  42 in total

Review 1.  Evolution of the internal fixation of long bone fractures. The scientific basis of biological internal fixation: choosing a new balance between stability and biology.

Authors:  Stephan M Perren
Journal:  J Bone Joint Surg Br       Date:  2002-11

2.  Post-operative outcomes of atypical femoral subtrochanteric fracture in patients on bisphosphonate therapy.

Authors:  B J X Teo; J S B Koh; S K Goh; M A Png; D T C Chua; T S Howe
Journal:  Bone Joint J       Date:  2014-05       Impact factor: 5.082

3.  Increased intracortical remodeling following fatigue damage.

Authors:  S Mori; D B Burr
Journal:  Bone       Date:  1993 Mar-Apr       Impact factor: 4.398

4.  Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy?

Authors:  Yong-Chan Ha; Myung-Rae Cho; Ki Hong Park; Shin-Yoon Kim; Kyung-Hoi Koo
Journal:  Clin Orthop Relat Res       Date:  2010-09-24       Impact factor: 4.176

5.  Bisphosphonate use and atypical fractures of the femoral shaft.

Authors:  Jörg Schilcher; Karl Michaëlsson; Per Aspenberg
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

6.  Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry.

Authors:  Jennifer E Hagen; Anna N Miller; Susan M Ott; Michael Gardner; Saam Morshed; Kyle Jeray; Timothy B Alton; Dennis Ren; W Parker Abblitt; James C Krieg
Journal:  J Bone Joint Surg Am       Date:  2014-11-19       Impact factor: 5.284

7.  Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls.

Authors:  Jörg Schilcher; Veronika Koeppen; Jonas Ranstam; Ralf Skripitz; Karl Michaëlsson; Per Aspenberg
Journal:  Bone       Date:  2012-10-22       Impact factor: 4.398

Review 8.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

9.  Propagation of bisphosphonate-related femoral stress fractures despite femoral nailing: a cautionary tale from 2 cases.

Authors:  Christian Fang; Jackie Yee-Man Chau; Siu-Bon Woo; Tak-Wing Lau; Kenny Kwan; Frankie Leung
Journal:  Geriatr Orthop Surg Rehabil       Date:  2014-03

10.  Risk of atypical femoral fracture during and after bisphosphonate use.

Authors:  Jörg Schilcher; Veronika Koeppen; Per Aspenberg; Karl Michaëlsson
Journal:  Acta Orthop       Date:  2015-01-13       Impact factor: 3.717

View more
  3 in total

1.  Increased rate of reoperation in atypical femoral fractures is related to patient characteristics and not fracture type. A nationwide cohort study.

Authors:  H P Bögl; K Michaëlsson; G Zdolsek; J Höijer; J Schilcher
Journal:  Osteoporos Int       Date:  2020-01-13       Impact factor: 4.507

2.  Surveillance of atypical femoral fractures in a nationwide fracture register.

Authors:  Hans Peter Bögl; Georg Zdolsek; Lukas Barnisin; Michael Möller; Jörg Schilcher
Journal:  Acta Orthop       Date:  2022-01-11       Impact factor: 3.717

Review 3.  Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures.

Authors:  Jessica Starr; Yu Kwang Donovan Tay; Elizabeth Shane
Journal:  Curr Osteoporos Rep       Date:  2018-08       Impact factor: 5.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.